重组人干扰素α1b联合双歧三联活菌治疗小儿轮状病毒性肠炎46例

Recombinant Human Interferon Alpha 1b Combined with Bifid Triple Viable for Treating Infantile Rotavirus Enteritis in 46 Cases

目的观察重组人干扰素α1b联合双歧三联活菌治疗小儿轮状病毒感染性肠炎的临床效果。方法根据就诊顺序将儿科2013年6月至2014年3月收治的92例患儿分为联合组和对照组,各46例。对照组采用常规治疗结合双歧三联活菌治疗,联合组在此基础上加用重组人干扰素α1b。结果联合组患儿的退热时间为(1.53±0.55)d、止泻时间为(2.08±0.55)d、住院时间为(3.2±1.2)d,均显著低于对照组的(2.36±0.69)d、(3.93±0.42)d、(5.5±1.5)d且差异显著(P<0.05);两组患儿的纠正脱水时间比较差异不显著(P>0.05)。治疗后第1,3天两组患儿的CD3+,CD4+,CD4+/CD8+较治疗前显著升高,CD8+则显著降低且差异显著(P<0.05),联合组的变化较对照组更显著(P<0.05)。联合组患儿治疗后的疗效分布显著优于对照组(P<0.05);联合组的总有效率为95.65%,显著高于对照组的80.43%(P<0.05)。结论重组人干扰素α1b联合双歧三联活菌治疗小儿轮状病毒感染性肠炎,可缩短治疗时间、增强患儿T细胞免疫能力,提高临床疗效。

Objective To observe the clinical effect of recombinant human interferon alPha 1b combined with Bifid TriPle Viable in the treatment of infantile rotavirus infectious enteritis. Methods 92 cases of rotavirus enteritis from June 2013 to March 2014 were selected and divided into combination grouP and control grouP according to visiting order,46 cases in each grouP. The control grouP used the conventional treatment combined with Bifid TriPle viable treatment;the combination grouP added with recombinant human interferon al-Pha 1b on the basis of the control. The ease situation,clinical curative effect and the related laboratory index of the two grouPs were comPared comParison. Results The fever abatement time was （ 1. 53 ± 0. 55 ） d,the antidiarrheal time and hosPitalization time were （ 2. 08 ± 0. 55 ） d and （ 3. 2 ± 1. 2 ） d in the combination grouP,which were significantly lower than （ 2. 36 ± 0. 69 ） d,（ 3. 93 ± 0. 42 ） d, （ 5. 5 ± 1. 5 ） d in the control grouP,and the difference was significant （ P 〈 0. 05 ）;the difference of dehydration time of Patients in two grouPs were not significant （ P 〉 0. 05 ） . After 1 d,3 d treatment,the CD3 ＋,CD4 ＋,CD4 ＋ /CD8 ＋ of the two grouPs were significantly in-creased, while CD8 ＋ decreased significantly and the difference was significant （ P 〈 0. 05 ） ,the increase of CD3 ＋,CD4 ＋, CD4 ＋ /CD8＋and the decrease of increased,CD8 ＋ in the combination grouP were more significantly than the control grouP （ P 〈 0. 05 ） . Effect distri-bution of combination grouP after treatment was significantly better than that in the control grouP （ P 〈 0. 05 ）;the total efficiency of the combination grouP was 95. 65% which was significantly higher than 80. 43% in control grouP with significant difference （ P 〈 0. 05 ） . Conclusion Recombinant human interferon alPha 1b combined with Bifid TriPle Viable caPsule in treating infantile rotavirusinfectious enteritis has shortened treatment time,can increase T cell immunity in children,and imProve clinical curative effect.